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Abstract  
For more than 30 years, antiepileptic drug development has been based on specific assumptions 
regarding the neurobiology of epilepsy but all marketed drugs have not changed the proportion of 
drug refractory patients. It is, therefore, evident that new molecular targets need to be identified. 
Advances in neurobiology and molecular pharmacology are bringing into the epilepsy field new 
neurochemical functions such as those modulated by cannabinoid, serotonin, melatonin and 
galanin receptors. Among all different compounds, the melatonin type 3 receptor agonist 
beprodone and cannabidiol are those at the more advanced stage of development. Interestingly, 
despite the structural analogies with tetrahydrocannabinol, the anticonvulsant activity of 
cannabidiol is not mediated by an interaction with cannabinoid receptors. Neurosteroids 
represent another remarkable class of drugs and among them ganaxolone is the one at the more 
advanced stage of development. Furthermore, for the first time, potential disease-modifying 
agents and techniques are entering the epilepsy market. Rapalogues such as everolimus and the 
antibiotic minocycline are currently under development for specific epileptic syndromes like 
tuberous sclerosis or Angelman syndrome.  Finally, optogenetics, though still at an early stage of 
development, represent a futuristic therapeutic strategy for drug-refractory epilepsies.  
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1. INTRODUCTION 
Antiepileptic drugs (AEDs) still remain the mainstay for the treatment of epilepsy but despite 
two decades in which a new compound was launched almost annually, 30% of patients still remain 
uncontrolled. It has been estimated that around 15 million people worldwide have drug refractory 
epilepsy [1] and many patients also have cognitive, psychological, psychiatric, and social 
impairments, as well as impaired quality of life and an increased risk of premature death [2]. It 
appears evident that new drugs are more than warranted but while many drugs can limit seizures, 
no drug can still prevent the underlying cause of epilepsy or the development of epilepsy 
(epileptogenesis) in patients who are at risk (e.g. following brain injury, stroke etc.). For these 
reasons, among all drugs currently under development, two groups are of interest: AEDs with new 
mechanisms of actions and potential disease modifying agents.  
The last three generations of compounds have focused basically on the same neurobiological 
targets, namely voltage-dependent ion channels, direct modulation of GABAergic and glutamatergic 
neurotransmission. Advances in neurobiology and molecular pharmacology are bringing into the 
epilepsy field new neurochemical pathways such as cannabinoid, serotonin, melatonin and galanin 
receptors.  Furthermore, for the first time, potential disease-modifying agents and techniques 
appeared in the epilepsy market. The mammalian target of rapamycin (mTOR) pathway now 
represents a major target in specific epilepsy syndromes as well as the antibiotic minocycline. 
Optogenetics may represent a new therapeutic strategy not only in genetic but also in post-stroke or 
post-traumatic epilepsies. 
 
2. NEW MECHANISMS OF ACTION 
2.1 Cannabinoid  
For many years, it has been speculated that cannabis, or some components of the cannabis plant, 
may have antiepileptic properties. It is now established that tetrahydrocannabinol (THC) has some 
anticonvulsant properties that are mediated by CB1 receptors, which are G protein-coupled cell 
membrane receptors expressed ubiquitously in neurons of the central nervous system [3]. However, 
the two major compounds currently under investigations do not exert antiepileptic effect through 
this pathway. In the case of cannabidiol (CBD), the mechanism of action is not entirely clarified but 
some authors proposed the inhibition of adenosine uptake as the main antiepileptic mechanism [4]. 
For cannabidivarin (CBDV), a homolog of CBD with the side-chain shortened by two methylene 
bridges, the mechanism of action is completely unknown and further research is needed [4]. Data on 
current trials involving CBD is summarised in Table 1. Despite the wide compassionate use, 
especially in children with drug-refractory epilepsy, data on efficacy is still contradictory and 
properly designed, high quality, and adequately powered trials are definitely needed [5]. 
2.2 Galanin  
Galanin is one of the most inducible neuropeptides. Its biosynthesis is increased 2 to 10-fold upon 
axotomy in the peripheral nerve and upon seizure activity in the brain [6]. This observation suggests 
that agonists of galanin receptors (GalR1–3) may be useful therapeutic agents in neuroprotection. 
GalR2 agonists seem to have anticonvulsant and analgesic/anxiolytic properties and a specific 
agonist (NAX 810-2) [4] is currently under preclinical investigation (Table 1).  
2.3 Serotonin  
The involvement of serotonin (5HT) pathways in epilepsy is based on data from animal models and 
human positron emission tomography (PET) imaging studies showing a role for 5HT-1A receptors in 
the pathophysiology of epilepsy [7]. In addition, many patients with epilepsy suffer from depression 
and anxiety, and the modulation of serotoninergic neurotransmission is a standard treatment for 
those disorders [8]. Nalutozan (PRX 0023) is a selective 5HT1A agonist currently under investigation 
[4]. Nalutozan has completed a clinical trial in anxiety and a randomized cross-over pilot study in 24 
patients with epilepsy is on-going. 
Another serotoninergic drug, not entirely new, is fenfluramine [9]. It was previously marketed for 
obesity as it has clear amphetamine-like effects but it is basically a serotonin reuptake inhibitor. 
Fenfluramine was withdrawn in 1997 after reports of heart valve disease and pulmonary 
hypertension, including cardiac fibrosis. On-going trials are investigating the compassionate use in 
Dravet syndrome.  
2.4 Melatonin  
Beprodone (VLB-01) is a melatonin type 3 receptor agonist under Phase IIb development in focal 
epilepsy [4]. It is supported by a large dataset from preclinical studies, including the maximum 
electroshock (MES) model, audiogenic seizures, strychnine, bicuculline and pentylenetetrazole (PTZ) 
model in mice and rats as well as Phase I and Phase II studies [4]. A 24-week, randomized, double-
blind, placebo-controlled trial of VLB-01 (1500 mg/day) in 224 patients (age 18—65 years) with focal 
epilepsy showed a 60% reduction in seizure frequency after 224 days as compared to 20% reduction 
for placebo [4]. Further studies are on-going. 
2.5 Neurosteroids  
Ganaxolone, SAGE-547 (allopregnanolone) and SAGE-217 are neuroactive steroids which act as 
positive allosteric modulators of both synaptic and extra-synaptic GABA-A receptors [4]. GABA-A 
receptors are widely regarded as validated drug targets for a variety of disorders, with decades of 
research and multiple approved drugs targeting these receptor systems. Proof-of-concept data for 
ganaxolone in the treatment of refractory paediatric seizures and as monotherapy for adult 
refractory focal onset seizures is now available and supports further investigations in specific 
paediatric syndromes [10]. SAGE-547 is an intravenous agent entering Phase III clinical development 
as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE), as well as an 
exploratory Phase IIA clinical trial for the treatment of essential tremor and as an adjunctive therapy 
for the treatment of severe postpartum depression [4].  SAGE-217 is still under preclinical 
development and showed robust efficacy in rodent models of seizures and status epilepticus [4]. In 
contrast to both allopregnanolone and ganaxolone, SAGE-217 possess a pharmacokinetic profile 
optimized for once daily oral administration but it has not been administered to human subjects to 
date, so no human pharmacokinetic data is available.  
2.6 Others  
Fenofibrate [11] is a peroxisome proliferator-activated receptor alpha agonist mimicking the 
metabolic changes induced by the ketogenic diet (KD). KD is a well-known treatment for epilepsy in 
selective cases [12], especially in paediatric syndromes, but it is burdened by a number of limitations 
such as being compliant with the diet, access to a specialist dietician service, difficulties in patients 
with swallowing problems etc. A clinical trial of fenofibrate in frontal lobe seizures is on-going. 
 
3. POTENTIAL DISEASE-MODIFYING AGENTS 
Rapamycin and derivative compounds (rapalogues) like everolimus, temsirolimus, 
deforolimus and ridaforolimusm target a group of serine/threonine protein kinase (mTOR) that 
regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, autophagy, and 
transcription. This class of drugs is already in use to prevent transplant rejection but some 
compounds are under investigations for autism, Alzheimer’s disease and cancer. Everolimus is a 
selective inhibitor of mTORC1 currently under Phase II development in patients with Tuberous 
Sclerosis Complex (TSC) [4]. TSC is a multisystem disease in which the hyper-activation of mTOR 
plays a key role in determining the characteristic pathologic lesions as well as the neurologic 
phenotype, including epilepsy. Everolimus was initially developed as an antitumoral agent and 
subsequently investigated in TSC. The effects of mTOR inhibition in mouse models of TSC were 
considered to be extremely important as they are more consistent with an antiepileptogenic effect 
rather than being only seizure suppressant [13]. However, it is important to note that everolimus 
failed to show any protective effect in the 6-Hz or PTZ seizure test [4].  
Minocycline is a tetracycline-class antibiotic which is known to inhibit microglial activation 
and proinflammatory cytokine release in animal models and experimental data shows that these 
immune processes may play a role in epileptogenesis [14]. In fact, preclinical studies have shown 
dose-dependent effects in abolishing focal seizures in the 6-Hz seizure test and in reducing after 
discharge duration in amygdala kindled rats [4]. At the moment there is a Phase I dose escalation 
study to explore safety and efficacy in moderate and severe traumatic brain injury in humans and 
other studies in amyotrophic lateral sclerosis and schizophrenia. An open label study in children with 
Angelman syndrome is ongoing. 
Finally, it is important to mention the role of optogenetics in the treatment of epilepsy [15]. 
Optogenetics is a combination of optical and genetic methods used to control the activity of specific 
populations of excitable cells using light with high temporal and spatial resolution. Derived from 
microbial organisms, 'opsin' genes encode light-activated ion channels and pumps. Opsins can be 
genetically targeted to well-defined neuronal populations in mammalian brains using viral vectors. 
Although invasive due to the need to inject a viral vector into the brain and implant a device to 
deliver light to opsin-transduced neurons, this approach has the potential to be effective in 
suppressing spontaneous seizures and may represent a new therapeutic strategy in both genetic and 
structural epilepsies (e.g. post-stroke or post traumatic brain injury epilepsy). However, this 
technique is still at an early stage of development and long-term safety and efficacy data are 
required in order to ensure the stability of opsin-expression for efficacy and to avoid toxicity that 
might result from foreign protein expression. 
 
4. CONCLUSION 
A wide variety of new molecular targets have been identified and compounds currently under 
development will undoubtedly cause a major change in treatment strategies for focal epilepsies. In 
addition, for the first time, potential disease-modifying agents and technologies are entering the 
epilepsy. Obviously, other agents, not listed in this editorial, are also under development. They 
mainly modulate usual targets such as AMPA receptors (BGG-492) or sodium channels (YKA-3089). 
In other cases (FV-082) the mechanism of action is entirely unknown. A detailed and 
comprehensive overview of the subject is available elsewhere [4, 10].  
 
5. EXPERT OPINION  
The current research scenario about investigational drugs for epilepsy is quite exciting 
although most of the compounds mentioned in this editorial are still at an early stage of 
development with some of them just at a preclinical stage. It is now evident that drugs with 
entirely new mechanisms of action are the only way to increase the number of seizure free 
patients as more than 20 antiepileptic drugs marketed so far have never changed the proportion 
of responders. This is obviously due to current animal models used to test anticonvulsant effect 
that probably screen for the usual mechanisms of action. New neurobiological models are urgently 
needed.   
Among new molecular targets, melatonin and galanin receptors are definitely interesting with 
promising data not only for epilepsy but also for pain, anxiety and depression. This is of great 
interest as epilepsy is now recognized as a disorder of the brain characterized not only by an 
enduring predisposition to generate epileptic seizures, but explicitly also by the neurobiological, 
cognitive, psychological, and social consequences of this condition. Psychiatric disorders are 
relatively frequent comorbidities in epilepsy, with a lifetime history identified in one out of three 
patients, and have a deleterious impact on quality of life, morbidity and mortality. New drugs 
addressing not only seizures but also potential comorbidities will allow tailored treatment 
strategies in selected populations. 
Robust safety data of these upcoming new compounds represents another key issue. In fact, 
although seizure freedom is an important predictor for quality of life, if it is at the expense of 
unacceptable side effects, adherence and quality of life may be poor. That many of the newer 
antiepileptic drugs have benefits in tolerability despite comparable efficacy almost certainly 
accounts for why some are now amongst first line options. Phase III studies will allow preliminary 
safety data although, as it happens in the majority of cases, phase IV post-marketing studies are 
the main source of information.  
Finally, for the first time, potential disease-modifying agents are entering the epilepsy market. 
This is a rather new concept in epilepsy research and it is still at an early stage of development. In 
terms of biological targets, it is important to distinguish between epileptic effectors (i.e. proteins 
that modulate seizure threshold) and epileptogenic mediators (i.e. proteins that control the 
expression or the functional state of the effectors). Everolimus represents a new class of drugs 
targeting the epileptogenic mediator rather than the epileptic effector. Data about safety are still 
preliminary and will represent a key issue as subjects with tuberous sclerosis represent a fragile 
subgroup of patients. Optogenetics is probably the most futuristic approach to the treatment of 
epilepsy. The ultimate challenge in epilepsy research still is to understand mechanisms whereby a 
healthy brain becomes epileptic. Optogenetics offers a solution to the problem until the final 
question will receive a definitive answer. However, a practical problem is how to design clinical 
trials for potential disease modifying agents. Epilepsy prevention trials are more complex, lengthy 
and costly than standard anti-seizure treatment trials for many reasons such as selection of 
suitable participants, consent for participation, duration of treatment, length of follow-up, and the 
identification of an appropriate end point. Key parameters of feasible clinical trial designs will 
need to be adapted to the specific intervention. Most previous anti-epileptogenesis trials with 
standard anti-seizure drugs that were aimed at preventing epilepsy following traumatic brain 
injury or stroke have been unsuccessful. Future trials should be focused on subgroups of 
populations with the highest risk of developing epilepsy (e.g. genetically predisposed individuals, 
patients with traumatic brain injury, stroke, central nervous system infections or de novo status 
epilepticus). In addition, data on risks as a function of time after insult in the different patient 
populations at risk may be helpful in determining whether therapeutic windows exist to optimize 
the design of prevention trials. Despite a century of clinical research in epilepsy, the majority of 
questions are still unresolved but it is time to move from empirical treatments to targeted and 
disease-modifying treatments. 
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Table 1. Summary of currently active studies identified in ClinicalTrials.gov and Ema.Europa.eu. 
 
Drug Phase CT number Syndrome 
Allopregnanolone (SAGE-
547)  
III NCT02477618 Super-refractory status epilepticus (SRSE) 
Beprodone (VLB-01) II NCT01179854 Adults drug-refractory focal epilepsy 
Cannabidiol I 
II 
II 
III 
III 
III 
NCT02286986 
NCT02324673 
NCT02332655 
NCT02224560 
NCT02224690 
NCT02224703 
Pediatric (2 - 19 years) drug-refractory 
epilepsy 
Pediatric (1-17 years) drug-refractory 
epilepsy 
Drug-refractory Sturge-Weber syndrome 
Lennox-Gastaut Syndrome  
Lennox-Gastaut Syndrome  
Dravet syndrome 
Everolimus II 
II 
NCT01997255 
NCT01713946 
Drug-refractory Sturge-Weber Syndrome 
Tuberous Sclerosis Complex drug-refractory 
seizures 
Fenofibrate II 2011-005433-
39 
Adults with nocturnal frontal lobe epilepsy 
Ganaxolone II 
III 
NCT02358538 
NCT01963208 
PCDH19 (Female Pediatric Epilepsy) 
Adult drug-refractory focal epilepsy 
Minocycline I 
II 
NCT01058395 
NCT02056665 
Traumatic brain injury 
Angelman syndrome 
Nalutozan (PRX-0023) II NCT01281956 Adults drug-refractory focal epilepsy 
NAX 810-2   Preclinical evidence only. Due to start 
Phase I 
 
 
 
 
 
 
